Sweden's Elicera Therapeutics Q2 loss widens

Elicera Therapeutics AB

28/08/2026 07:12

Overview
Sweden CAR T-cell therapy developer's Q2 operating loss widened yr/yr
Loss per share for Q2 increased to SEK -0.12 from SEK -0.06 yr/yr
Company raised SEK 54.6 mln in rights issue to fund clinical programs

Outlook
Company says strengthened financial position will fund completion of CARMA study patient recruitment
Elicera plans to accelerate preparations for first clinical study with ELC-401
Company says next step in ELC-100 program is still under evaluation

Result Drivers
CARMA STUDY RESULTS - Co reported 91% tumor response rate in patients treated in CARMA study, including disease control in those who had relapsed after prior CAR T therapy
REGULATORY MILESTONE - Co received supportive feedback from Swedish MPA for planned clinical study with ELC-401 in glioblastoma
RIGHTS ISSUE - Co raised SEK 54.6 mln in rights issue to fund completion of CARMA study and preparations for ELC-401 clinical trial

Company press release: ID:nWkr8F1Mwz

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Adjusted Loss Per Share
 
SEK 0.12
 

Analyst Coverage
Wall Street's median 12-month price target for Elicera Therapeutics AB is SEK7.51, about 191.6% above its August 27 closing price of SEK2.58

Reuters Recommended Reads
Aug 27 - Sweden's BioInvent Q2 net sales drop, loss widens
Aug 27 - China's JW Therapeutics interim revenue rises 4.7% on Carteyva sales
Aug 26 - Bristol Myers ends blood cancer drug deal with cell therapy maker Cellares

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)